Premium
Evaluation of monotherapy of intravitreal Bevacizumab in retinopathy of prematurity stage 3 plus
Author(s) -
Shirzadeh S.
Publication year - 2016
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2016.0310
Subject(s) - medicine , retinopathy of prematurity , bevacizumab , ophthalmology , fundus (uterus) , retinal , stage (stratigraphy) , surgery , chemotherapy , gestational age , pregnancy , paleontology , genetics , biology
Purpose Evaluation of monotherapy of Bevacizumab intravitreal effect in Retinopathy Of Prematurity stage 3 plus treatment Methods 158 eyes of 89 premature infants with threshold ROP 3 plus disease which 86 (51.2%) in zone I and 82 (48.8%) in zone II, were treated with intravitreal injection of 0.625 mg in 0.025 cc bevacizumab that 11eyes (7%) were treated with second injection. No prior laser or other intravitreal therapy was done. Fundus examination was performed prior to the intervention and at each follow‐up visit. Changes in various mean vital parameters 1 week post intervention compared to pre‐intervention were assessed. Results Any infant wasn't any problem post intravitreal bevacizumab injection. After 4–161 days (mean 17.62), all eyes showed complete traet the puls disease and after 4–278 days (mean: 44.39) all eyes showed complete retinal vascularisation without any signs of disease recurrence. Conclusions Treatment of ROP stage III puls disease with intravitreal Bevacizumab was effective in all cases and should be considered for treatment. Any side effect of Bevacizumab was seen. More patients with longer follow‐up duration are mandatory to confirm the safety and efficacy of this treatment.